News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

PRB Pharmaceuticals And Lee Pharmaceuticals (LPHM) Release: VIRA 38 Production Capacity Increased To Meet The Needs Of Bird Flu Afflicted Nations

10/19/2005 5:09:36 PM

HONG KONG, July 15 /PRNewswire/ -- PRB Pharmaceuticals and Lee's Pharmaceuticals announced today that they have stepped up production capacity of VIRA 38. "As we move closer to the emergence of an influenza pandemic, we find personal stockpiling of VIRA 38 becoming more widespread," said Dr. Charles Hensley, Chairman and CEO of PRB Pharmaceuticals. "In life or death situations, people tend to take matters into their own hands rather than relying on government institutions."

"People are very concerned about the lack of adequate government stockpiles of anti-viral medications. This is especially true in developing countries, many of which are afflicted with bird flu. Unfortunately, wealthy Western nations were allowed to purchase most of the world's supply of prescription anti-viral medications," added Dr. Hensley. "Starting with this production cycle, we are earmarking 50% of our inventory for people in developing nations. From a humanitarian and world health perspective, keeping these nations supplied with medication is the correct thing to do."

PRB Pharmaceuticals has a strong presence in Southeast Asia and the company has recently started working with Vietnam government officials to help bring the bird flu crisis under control.

VIRA 38 first gained notoriety during the Taiwan SARS outbreak of 2003 when it was used by the Taiwan Presidential staff and doctors at Sungshan Hospital (SARS management facility) and again in the spring of 2004 when it was discovered that compounds in VIRA 38 block bird flu virus (H5N1) infections.

About VIRA 38

VIRA 38, PRB Pharmaceuticals' over-the-counter broad spectrum anti-viral medication, is known for its effectiveness in treating and preventing influenza. VIRA 38 has recently been shown to contain compounds that inhibit the bird flu (H5N1) virus. Researchers at the Chinese University of Hong Kong have previously discovered these same compounds to be effective against a variety of pathogens, including SARS CoV, the virus responsible for causing severe acute respiratory syndrome.

About PRB Pharmaceuticals

PRB Pharmaceuticals, Inc. ( ) is based in Irvine, California, and Hong Kong. PRB Pharmaceuticals is a fully integrated biopharmaceutical company that develops unique and highly efficacious anti-viral treatments and preventative therapies.

About Lee's Pharmaceuticals

Lee's Pharmaceutical Holdings Ltd ( ) (Hong Kong Exchange GEM Stock:8221) distributes VIRA 38 to the Hong Kong market. Lee's is an integrated research-driven and market-oriented pharmaceutical company engaged in the development, manufacture and sales of quality biopharmaceutical products that focus on combating cardiovascular and viral diseases.

Web sites: http://www.prbpharmaceuticals.com For further information: Vivian Fung +852-2314-1282, +852-2314-1708 (Fax) Charles B. Hensley, Ph.D. Chairman & Chief Executive Officer PRB Pharmaceuticals

This release was issued through eReleases(TM). For more information, visit .

PRB Pharmaceuticals, Inc.

CONTACT: Vivian Fung in Hong Kong, +011-852-2314-1282, or fax,+011-852-2314-1708, or Charles B. Hensley, Ph.D., Chairman & ChiefExecutive Officer,, both of PRBPharmaceuticals

Read at

comments powered by Disqus